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Introduction
Placenta accreta is strongly related to antepartum 
and postpartum hemorrhage. Based on the depth of
trophoblast invasion and disease severity, it may include
placenta accreta vera, placenta increta, and placenta
percreta. The prenatal diagnosis is aided by a combi-
nation of grayscale and color Doppler ultrasonography
[1]. Although the pathogenesis of placenta accreta is
characterized at the microscopic (poor decidualization
with intramyometrial infiltration of the villous tissues)
and macroscopic (profuse uteroplacental neovasculari-
zation in the region of interest) levels, there have been
few reports on the molecular milieu of this disorder
[2,3].
Earl et al published an immunohistochemical study
of four cases using antibodies against cell membrane
antigens, placental hormones, and cytokeratins [2].
They concluded that placenta accreta is not associated
with increased capacity for proliferation or invasiveness
in trophoblast populations. Further, Hochner-Celnikier
et al investigated four factors indicative of trophoblast
invasiveness in 20 cases and concluded that the patho-
genesis of placenta accreta is not related to over-
invasiveness of the trophoblasts [3].
The modulation of trophoblast migration and inva-
sion during normal placental development is inter-
dependently influenced by different kinds of molecules,
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such as growth factors and their receptors, cytokines,
hormones, adhesion molecules, and enzymes, in an
autocrine or paracrine manner [4–6]. Through tight
spatial and temporal regulation, placental villi do not
proceed beyond the inner third of the myometrium
[7–9]. Clinically, loss of balance between trophoblast
invasion and the maternal decidual defense barrier
may result in preeclampsia and intrauterine growth
retardation (IUGR) (under-invasion) or gestational tro-
phoblastic disease and placenta accreta (over-invasion)
[10–12].
Decidual maldevelopment in placenta accreta, a
common histologic finding, is usually caused by previ-
ous cesarean sections or uterine curettages. Due to the
decreased production of tissue inhibitor of metallo-
proteinase (TIMP) and transforming growth factor-
resulting from decidual defects, the proliferation, migra-
tion, and invasiveness of trophoblast populations might
be changed significantly [13,14]. In contrast, an in vitro
co-culture study showed no significant increase in cyto-
trophoblast invasion even without a decidual endo-
thelial cell monolayer [15]. Clearly, in addition to the
well-known risk factor of decidual maldevelopment,
the regulatory factors influencing the occurrence of pla-
centa accreta are complex and need to be elucidated.
Therefore, we hypothesized that the pathogenesis
of placenta accreta involves abnormal expression of
growth-, angiogenesis- and invasion-related factors in
trophoblast populations.
Epidermal Growth Factor Receptor 
and c-erbB-2 Oncoprotein
Trophoblast invasion during human placentation is a
highly complicated process involving cellular prolifera-
tion, migration and differentiation. Tyrosine kinase
receptors are known to be involved in these processes.
Epidermal growth factor receptor (EGFR) and the 
c-erbB-2 oncoprotein are structurally and functionally
related tyrosine kinase receptors, expressed in high
amounts in human placenta [5].
We demonstrated using immunohistochemistry that
expression of EGFR in the syncytiotrophoblast was sig-
nificantly higher in cases than controls (p0.03), while
the immunoreactivity of c-erbB-2 was significantly lower
in cases than controls (p < 0.001). However, no signifi-
cant difference in the expression of EGFR and c-erbB-2
in the villous and extravillous cytotrophoblastic cells was
noted between cases and controls. Western blot analy-
ses showed an increase in EGFR expression in three of
four placenta accreta specimens compared with normal
placental tissues from the same trimester [16].
Vasculoendothelial Growth Factor,
Placenta Growth Factor, and 
Their Receptors
Vasculoendothelial growth factor (VEGF), placenta
growth factor (PlGF), and their receptors (VEGFR-1, 
-2 and -3) are well-known angiogenic factors [17–21].
VEGF, VEGF-B and PlGF bind to VEGFR-1/Flt-1; VEGF
and VEGF-C bind to VEGFR-2/KDR; and VEGF-C binds
to VEGFR-3/Flt-4 [22–26]. During normal pregnancy,
the expression of VEGF and its receptors in the tro-
phoblasts regulates the secretion of a wide range of
proteins and hormones [18,27]. Soluble isoforms of
VEGFR, sVEGFR-1 and sVEGFR-2 regulate the biologi-
cal activities of PlGF and VEGF [28,29]. Accumulating
evidence indicates that these proteins are involved in
the pathogenesis of placental disorders. In hypoxic/
ischemic regions of pathologic placentas, expression 
of PlGF and VEGFR-1 is enhanced in villous tropho-
blasts via autocrine regulation, whereas expression of
VEGF and VEGFR-2 is increased within the villous ves-
sels through paracrine regulation [21]. Villi from missed
abortion and blighted ovum show diminished immuno-
reactivity of VEGF in the trophoblasts, VEGFR-1 in the
syncytium, and VEGFR-2 in the trophoblasts [30].
Furthermore, increased VEGFR-1 expression in the tro-
phoblasts from pregnancies complicated by preeclamp-
sia and IUGR indicates abnormal placental function
and hypoxia [31]. Increased sVEGFR-1 might explain
the low PlGF concentrations found in preeclamptic
subjects [31,32].
We have shown that VEGFR-2 expression in syncy-
tiotrophoblast, rather than villous and extravillous cyto-
trophoblasts, is significantly lower in cases than controls
in both the second and third trimesters (p0.005 
and 0.002, respectively) [33]. However, expression of
VEGFR-1 and VEGFR-3 in trophoblast populations 
was not significantly different in controls and cases
(p > 0.05). Endothelial cells of the larger vessels in
specimens from placenta accreta stained stronger for
Ki-67 (a proliferating cell nuclear antigen marker) than
those from normal placenta. Western blot analyses
and reverse transcription polymerase chain reaction
(RT-PCR) showed that VEGFR-2 expression corre-
lated with the trend in immunohistochemical data
(p < 0.05). Furthermore, enzyme-linked immunosor-
bent assay (ELISA) on the placental lysates showed that
women with placenta accreta had significantly higher
VEGF (p0.001) and lower sVEGFR-2 concentrations
(p0.015) than those with normal pregnancy. However,
PlGF and sVEGFR-1 concentrations did not show a dra-
matic difference between cases and controls (p0.149
and 0.354, respectively).
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Consensus exists that VEGF family molecules 
are important for both nonendothelial and endothe-
lial effects in physiologic and pathologic processes
[31,34,35]. In our study, VEGFR-2 in cases compli-
cated by placenta accreta showed significantly lower
expression in the syncytiotrophoblast, which may 
indirectly depress the effects of human chorionic gona-
dotropin and human placental lactogen on tropho-
blast invasion and angiogenesis [36–38]. Therefore,
decreased VEGFR-2 expression is probably not a change
specific to placenta accreta, but is associated with the
fine balance between expression of pro- and anti-invasive
factors within the decidual layer and uterine myome-
trium to regulate the depth and rate of placental inva-
sion. The impact of the reduction of membrane-bound
VEGFR-2 on placenta accreta remains to be eluci-
dated. sVEGFR-1, which antagonizes VEGF function,
has been implicated in the pathophysiology of pre-
eclampsia [39,40]. Similar to sVEGFR-1, sVEGFR-2 has
regulatory consequences with respect to VEGF-mediated
angiogenesis as well as the potential to serve as a
quantitative biomarker of angiogenesis [29]. In addi-
tion, the isolated sVEGFR-2 fragment can inhibit tumor
angiogenesis in vivo [41]. Increased VEGF together with
decreased sVEGFR-2 placental concentrations imply
paracrine induction of neovascularization during the
development of placenta accreta. The stronger immu-
nohistochemical expression of Ki-67 in endothelial
cells of larger blood vessels might further support 
the potential actions of VEGF on the development of 
the uteroplacental neovascularization typical of placenta
accreta.
Angiopoietins and Receptors
Although the role of the angiopoietin/Tie receptor sys-
tem in vasculogenesis and angiogenesis has been pre-
viously investigated, little is known about its role in
diseases other than malignancies [42]. Tie-1 (tyrosine
kinase with immunoglobulin and epidermal growth
factor homology domains) and Tie-2 (tunica internal
endothelial cell kinase) receptors have been regarded as
specific vascular endothelial markers [43]. The ligand
for Tie-1 has not been identified, and it is unclear
whether Tie-1 is functionally similar to Tie-2 [44]. Tie-2
has three known ligands: angiopoietin-1 (Ang-1), Ang-2,
and Ang-4 [45]. In situ hybridization studies have
detected Ang-1 and Tie-2 in the trophoblast bilayer of
a first-trimester placenta, whereas Ang-2 mRNA is
restricted to the cytotrophoblast, suggesting that they
have a role in trophoblast function during early embry-
onic development (e.g., nitrous oxide release and 
trophoblast migration) [46]. These data imply a speci-
fic role for Ang-1, Ang-2, and their receptor Tie-2 in
normal and pathologic human placentas. Pertubation
of this would result in acute and chronic changes in
placental vascular structure and trophoblast function,
such as IUGR, preeclampsia, and recurrent abortion
[30,47–49].
We have found that immunohistochemical expres-
sion of Tie-2 in syncytiotrophoblast, rather than in
cytotrophoblastic and extravillous trophoblastic cells,
is significantly lower in cases than controls (p0.015
and 0.025, respectively) [50]. Decreased expression of
Tie-2 protein is observed by Western blot analysis in
placental accreta specimens compared with tissue from
normal placentas from the same trimester (p < 0.05).
These results are similar to the trends of immunohisto-
chemical results in syncytiotrophoblasts. However, there
is no obvious trend in Tie-1 protein expression between
cases and controls (p > 0.05). ELISA in the placental
lysates reveals significantly higher Ang-2 (p0.026)
and lower Tie-2 concentrations (p0.003) in women
with placenta accreta than those with a normal preg-
nancy. However, there is no significant difference in
Ang-1 placental levels between the groups (p0.260).
Furthermore, Ang-2 shows a higher expression in the
syncytiotrophoblast of placental villi from placenta
accreta than those from normal placental tissues in
both the second and third trimesters (p0.005 and
0.012, respectively).
Consensus also exists that Tie receptors and their
ligands (angiopoietins) are responsible for a number
of nonendothelial and endothelial effects in both
physiologic and pathologic processes during placental
development [30,43,46–48]. The presence of func-
tional Tie-2 receptors in trophoblasts demonstrates 
a specific role for angiopoietins as regulators of tro-
phoblast behavior in placental development [51]. 
The interactions between Tie-2 and its ligands (Ang-1
and Ang-2) are involved in the well-prepared endo-
metrium, trophoblast invasion, and remodeling of the
maternal vasculature during the peri-implantation stage
[52]. With longer exposure or at higher concentra-
tions, Ang-2 acts as a Tie-2 agonist (or a partial ago-
nist) in cultured endothelial cells [46,53]. Despite
Ang-1-induced Tie-2 phosphorylation being essential
to initiate angiogenesis, several studies have demon-
strated that Ang-2 and VEGF alone can promote a
rapid increase in capillary diameter, remodeling of the
basal lamina, and new vessel growth, evidenced by
sprouting of existing blood vessels [54–56]. Thus, the
increased placental Ang-2 level in our study, with the
concomitantly upregulated VEGF expression found pre-
viously [33], would result in an overall destabilization
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of uterine vasculature and enhance the neovascularized
phenomenon found in placenta accreta. In a variety of
invasive, highly vascular malignancies [57–60], Ang-2
exhibits overexpression and is responsible for tumorige-
nesis, vasculature remodeling, and tumor progression.
Although Tie-2 is overexpressed in colorectal carci-
noma, it is not remarkably expressed in pancreatic car-
cinoma. Therefore, the decreased Tie-2 expression in
syncytiotrophoblasts found in our study might imply 
a negative feedback response rather than a primary
event during the formation of the profuse vascular net-
works responsible for massive peripartum hemorrhage.
Matrix Metalloproteinase and TIMP
The extracellular matrix proteolytic machinery is known
to play a major role in trophoblast invasion, a process
that shares similar features with the pathology of
tumor invasion [61]. Trophoblast invasion involves the
degradation of extracellular matrix components by dif-
ferent kinds of enzymes [62]. The zinc-requiring matrix
metalloproteinase (MMP) family is considered to be
primarily responsible for matrix degradation and plays
an important role in angiogenesis [63,64]. Four main
groups, including collagenases, gelatinases, stromely-
sins, and membrane-type (MT) MMPs, have been cate-
gorized with at least 20 members [65,66]. MMP-2 and
MMP-9 (type IV collagenases) are particularly impor-
tant for the penetrative ability of cytotrophoblasts in vitro
and in vivo [13,63,67,68]. MT1-MMP and MT2-MMP
have also been shown to play a crucial role in 
trophoblast invasion [9,69,70]. Both are potential
membrane-associated physiologic activators of MMP-2
and are expressed by proliferating and invasive tro-
phoblasts during pregnancy [69–72]. Furthermore,
the expression of MMPs is regulated by TIMP. TIMP-1
(an inhibitor of all known MMPs) and TIMP-2 (a pre-
ferential inhibitor of MMP-2) [73,74] are expressed by
decidual cells and, to a certain degree, by extravillous
trophoblasts [62,75–77].
We have shown that immunoreactive bands on
Western blot analyses indicate that expression of both
66- and 60-kDa forms of MT1-MMP in second-trimester
placentas and the 68-kDa form of MT2-MMP in third-
trimester placentas are significantly decreased in tis-
sues from placenta accreta (p0.025, 0.006, and
0.043, respectively; unpublished data). All other protein
factors studied (MMP-2, MMP-9, TIMP-1, TIMP-2) were
not significantly different in complicated and uncom-
plicated pregnancies (p > 0.05). RT-PCR for these fac-
tors did not demonstrate significant differences between
the two groups (p > 0.05).
We found that MMP family molecules were not sig-
nificantly upregulated in placenta accreta. Therefore,
the association of these invasion-related molecules
with placenta accreta is unlikely. We have found that 
upregulated EGFR, VEGF and Ang-2 are related to the
development of placenta accreta [16,33,50]. Although
the induction of MT1-MMP has the ability to upregulate
EGFR, VEGF and Ang-2 [78–81], the decreased expres-
sion of MT-MMPs in placenta accreta shown in our
study may represent in situ downregulation or negative
feedback by other microenvironmental factors.
Conclusion
The pathogenetic mechanisms of placenta accreta are
complicated and multifactorial. Although our data are
not supported by animal disease models, we believe
that growth-, angiogenesis- and invasion-related fac-
tors may play an additive or synergistic role in the
pathogenesis of placenta accreta. In addition, we
acknowledge that decidual defect is still a major con-
tributing factor in the formation of placenta accreta.
The impact of stromal and/or myometrial factors, which
allow trophoblasts to invade deep into the myome-
trium, needs to be clarified. Further studies are needed
in order to understand the responsible signaling mole-
cules and possible genetic events, with intrauterine
medical therapy as the ultimate goal.
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